DK3377534T3 - Behandling af lungecancer ved hjælp af en kombination af et anti-pd-1-antistof og et anti-ctla-4-antistof - Google Patents

Behandling af lungecancer ved hjælp af en kombination af et anti-pd-1-antistof og et anti-ctla-4-antistof

Info

Publication number
DK3377534T3
DK3377534T3 DK16819718.4T DK16819718T DK3377534T3 DK 3377534 T3 DK3377534 T3 DK 3377534T3 DK 16819718 T DK16819718 T DK 16819718T DK 3377534 T3 DK3377534 T3 DK 3377534T3
Authority
DK
Denmark
Prior art keywords
antibody
ctla
treatment
combination
lung cancer
Prior art date
Application number
DK16819718.4T
Other languages
English (en)
Inventor
Nathan E Faith
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57680484&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3377534(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK3377534T3 publication Critical patent/DK3377534T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK16819718.4T 2015-11-18 2016-11-18 Behandling af lungecancer ved hjælp af en kombination af et anti-pd-1-antistof og et anti-ctla-4-antistof DK3377534T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562257139P 2015-11-18 2015-11-18
US201662345314P 2016-06-03 2016-06-03
PCT/US2016/062884 WO2017087870A1 (en) 2015-11-18 2016-11-18 Treatment of lung cancer using a combination of an anti-pd-1 antibody and an anti-ctla-4 antibody

Publications (1)

Publication Number Publication Date
DK3377534T3 true DK3377534T3 (da) 2025-08-18

Family

ID=57680484

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16819718.4T DK3377534T3 (da) 2015-11-18 2016-11-18 Behandling af lungecancer ved hjælp af en kombination af et anti-pd-1-antistof og et anti-ctla-4-antistof

Country Status (18)

Country Link
US (3) US11072657B2 (da)
EP (2) EP4609915A3 (da)
JP (3) JP2018538263A (da)
KR (2) KR20180071386A (da)
CN (1) CN108350081A (da)
DK (1) DK3377534T3 (da)
ES (1) ES3034582T3 (da)
FI (1) FI3377534T3 (da)
HR (1) HRP20250902T1 (da)
HU (1) HUE072729T2 (da)
LT (1) LT3377534T (da)
PL (1) PL3377534T3 (da)
PT (1) PT3377534T (da)
RS (1) RS67037B1 (da)
SI (1) SI3377534T1 (da)
SM (1) SMT202500282T1 (da)
TW (3) TWI821748B (da)
WO (1) WO2017087870A1 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113967253A (zh) * 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
TN2017000440A1 (en) * 2015-04-17 2019-04-12 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
HRP20250902T1 (hr) * 2015-11-18 2025-09-26 Bristol-Myers Squibb Company Liječenje raka pluća korištenjem kombinacije anti‑pd‑1 antitijela i anti‑ctla‑4 antitijela
EP4491237A3 (en) * 2016-10-28 2025-03-26 Bristol-Myers Squibb Company Methods of treating urothelial carcinoma using an anti-pd-1 antibody
US20200239577A1 (en) 2017-10-15 2020-07-30 Bristol-Myers Squibb Company Methods of treating tumor
CA3081696A1 (en) * 2017-11-07 2019-05-16 Memorial Sloan Kettering Cancer Center Inhibition of ctla-4 and/or pd-1 for regulation of t cells
EP3774911A1 (en) * 2018-03-30 2021-02-17 Bristol-Myers Squibb Company Methods of treating tumor
EP3938396A1 (en) * 2019-03-11 2022-01-19 Jounce Therapeutics, Inc. Anti-icos antibodies for the treatment of cancer
EP3937979A4 (en) * 2019-03-13 2023-03-08 Merck Sharp & Dohme LLC COMBINATIONAL ANTI-CANCER THERAPIES WITH CTLA-4 AND PD-1 BLOCKING AGENTS
KR20210146348A (ko) * 2019-03-28 2021-12-03 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
CN113891748A (zh) * 2019-03-28 2022-01-04 百时美施贵宝公司 治疗肿瘤的方法
AR122043A1 (es) * 2020-05-12 2022-08-03 Bristol Myers Squibb Co Dosificación y administración del anticuerpo anti-ctla-4 activable
US20230295301A1 (en) * 2020-07-21 2023-09-21 Shanghai Junshi Biosciences Co., Ltd. Anti-ctla-4 antibody and use thereof
WO2022087402A1 (en) 2020-10-23 2022-04-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
KR20230107309A (ko) 2020-11-10 2023-07-14 카탈임 게엠베하 항-gdf15 항체 및 암 치료용 투여 용법
EP4294531A4 (en) * 2021-02-18 2025-07-16 Qilu Puget Sound Biotherapeutics Corp COMBINATIONS OF ANTI-PD1 AND ANTI-CTLA4 ANTIBODIES
WO2024002074A1 (zh) * 2022-06-28 2024-01-04 齐鲁制药有限公司 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1261376A1 (en) 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
CA2647282A1 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
WO2009100140A1 (en) * 2008-02-04 2009-08-13 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
CN102203132A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
CA2777226A1 (en) * 2009-10-12 2011-04-21 Pfizer Inc. Cancer treatment
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
CA2828940C (en) 2011-03-10 2024-04-16 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
CN113967253A (zh) * 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
CA2877414A1 (en) * 2012-07-30 2014-02-06 Alex Wah Hin Yeung Live and in-vivo tumor specified cancer vaccine system
US20150231241A1 (en) * 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US9789182B2 (en) * 2012-10-23 2017-10-17 Bristol-Myers Squibb Company Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
EP3068425B1 (en) * 2013-11-11 2021-01-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EA201691376A1 (ru) 2014-02-04 2017-01-30 Пфайзер Инк. Комбинация антагониста pd-1 и ингибитора vegfr для лечения рака
JP2017515859A (ja) 2014-05-15 2017-06-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置
CA2955676A1 (en) * 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
US20160362489A1 (en) * 2015-04-28 2016-12-15 Bristol-Myers Squibb Company Treatment of PD-L1-Positive Melanoma Using an Anti-PD-1 Antibody
CN107735097A (zh) * 2015-04-30 2018-02-23 希斯托金公司 用于治疗癌症或免疫性疾病的细胞外基质组合物
WO2016191751A1 (en) 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
JP2018522887A (ja) * 2015-07-14 2018-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 免疫チェックポイント阻害剤を使用する癌の処置法
HRP20250902T1 (hr) * 2015-11-18 2025-09-26 Bristol-Myers Squibb Company Liječenje raka pluća korištenjem kombinacije anti‑pd‑1 antitijela i anti‑ctla‑4 antitijela
WO2017132508A1 (en) 2016-01-27 2017-08-03 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
MA44483A (fr) * 2016-03-24 2019-01-30 Millennium Pharm Inc Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
WO2017176925A1 (en) 2016-04-05 2017-10-12 Bristol-Myers Squibb Company Cytokine profiling analysis for predicting prognosis of a patient in need of an anti-cancer treatment
WO2017210631A1 (en) 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer
WO2017210624A1 (en) 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treating a tumor
EP3774911A1 (en) * 2018-03-30 2021-02-17 Bristol-Myers Squibb Company Methods of treating tumor
JP2022505647A (ja) * 2018-10-23 2022-01-14 ブリストル－マイヤーズ スクイブ カンパニー 腫瘍の処置方法

Also Published As

Publication number Publication date
US20180371092A1 (en) 2018-12-27
RS67037B1 (sr) 2025-08-29
US11072657B2 (en) 2021-07-27
HRP20250902T1 (hr) 2025-09-26
TW202227132A (zh) 2022-07-16
PL3377534T3 (pl) 2025-09-01
EP3377534A1 (en) 2018-09-26
PT3377534T (pt) 2025-07-10
SMT202500282T1 (it) 2025-09-12
EP4609915A3 (en) 2025-11-19
FI3377534T3 (fi) 2025-08-22
TW201731527A (zh) 2017-09-16
TWI821748B (zh) 2023-11-11
KR20180071386A (ko) 2018-06-27
WO2017087870A1 (en) 2017-05-26
KR20260020215A (ko) 2026-02-10
JP2018538263A (ja) 2018-12-27
US20250154257A1 (en) 2025-05-15
US12528865B2 (en) 2026-01-20
ES3034582T3 (en) 2025-08-20
EP4609915A2 (en) 2025-09-03
TWI912619B (zh) 2026-01-21
TW202408573A (zh) 2024-03-01
JP2025029025A (ja) 2025-03-05
SI3377534T1 (sl) 2025-09-30
LT3377534T (lt) 2025-08-11
US20220017619A1 (en) 2022-01-20
CN108350081A (zh) 2018-07-31
JP2022068352A (ja) 2022-05-09
TWI795347B (zh) 2023-03-11
EP3377534B1 (en) 2025-06-18
HUE072729T2 (hu) 2025-12-28

Similar Documents

Publication Publication Date Title
DK3377534T3 (da) Behandling af lungecancer ved hjælp af en kombination af et anti-pd-1-antistof og et anti-ctla-4-antistof
IL289600A (en) Compositions comprising a combination of an anti–pd–1 antibody and another antibody
DK3455259T5 (da) Kombination af anti-PD-1-antistoffer og stråling til cancerbehandling
DK3565844T3 (da) Fremgangsmåder til behandling af cancer med anti-PD-1-antistoffer
DK3458478T3 (da) Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling
DK3394103T3 (da) Kombination af anti-PD-1-antistoffer og bispecifikke anti-CD20-/anti-CD3-antistoffer til cancerbehandling
IL259713A (en) Anti-dr5 antibodies and methods of use thereof
DK3178849T3 (da) Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer
DK3142751T3 (da) Anti-B7-H1- og anti-CTLA-4-antistoffer til behandling af ikke-småcellet lungecancer
DK3551660T5 (da) Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
DK3826667T3 (da) Claudin6-antistoffer og fremgangsmåder til behandling af kræft
DK3699198T3 (da) Fremgangsmåder til tumorbehandling ved hjælp af bispecifikke CD3XCD20-antistoffer
DK3541841T3 (da) Anti-PD-1-antistoffer og sammensætninger
DK3303394T3 (da) Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
DK3166976T3 (da) Anti-pd-l1-kombinationer til behandling af tumorer
DK3307322T3 (da) Humaniserede anti-cd40-antistoffer og anvendelser deraf
DK3189082T3 (da) Anti-pd-l1-konjugater til behandling af tumorer
DK3331915T3 (da) Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere
DK3230319T3 (da) Anti-PD-1-antistoffer og fremgangsmåder til anvendelse deraf
DK3193929T3 (da) Behandlingsregimer ved anvendelse af anti-nkg2a-antistoffer
DK3295951T3 (da) Anti-pvrig-antistoffer og fremgangsmåder for anvendelse
DK4339615T3 (da) Anti-PD-1-antistof til anvendelse i behandlingen af kræft
DK3129018T3 (da) Behandling af NAFLD og NASH
DK3483593T3 (da) Luminescent-oxygen-channeling-immunoassay ved anvendelse af tre antistoffer og fremgangsmåder til fremstilling og anvendelse deraf
DK3292153T3 (da) Kombination af en cd30xcd16a-antistof med en anti-pd-1 antagonistisk antistof til behandling